- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT02089841
Efficacy of Artemether/Lumefantrine for the Treatment of Uncomplicated Malaria. (ALE)
Efficacy of Artemether/Lumefantrine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Children Five Years After Wide Scale Use of the Drug in Tanzania.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Artemisinin based combination therapies (ACTs) are currently recommended by the World Health Organization (WHO) as first-line treatment for uncomplicated malaria in all malaria endemic countries including Tanzania, that adopted the policy in 2007. ACTs have proven to be highly efficacious in different parts of the world with different malaria endemicity. Artemisinins clear asexual parasites rapidly and they are also potent against P. falciparum gametocytes, hence reducing disease transmission and spread of drug resistance. Nonetheless, a report in Kenya shows an increase in proportion of patients with parasitaemia on day 1. Most recently, resistance against artemisinins has been confirmed in four countries of South-East Asia, and it may spread to Africa.
In order to safeguard ACTs life span, WHO recommends all suspected malaria cases to be confirmed with parasitological diagnosis, followed by prompt treatment with effective antimalarials. It also emphasizes on the need to conduct efficacy studies for the first and second line antimalarial treatments after every two years so as to be able to detect resistance early on its course. Therefore, based on this notion, this study aimed to assess the therapeutic efficacy of Artemether/Lumefantrine among children with uncomplicated falciparum malaria in Bagamoyo district, five years after its wide scale use in Tanzania.
Studietype
Registrering (Faktiske)
Fase
- Fase 4
Kontakter og plasseringer
Studiesteder
-
-
-
Dar es Salaam, Tanzania, P.O Box 65001
- Muhimbili University of Health and Allied Sciences
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Mono-infection with P. falciparum
- Parasitaemia level of 2000 - 200,000/μL
- Absence of danger signs or signs of severe malaria
- Axillary temperature ≥ 37.5°C or history of fever 24 hours prior to coming to the facility
- Absence of other concomitant infections like pneumonia which can cause fever
- No use of antimalarial drug two weeks prior to the study
- Consent to comply to the protocol.
Exclusion Criteria:
- Presence of general danger signs or signs of severe falciparum malaria
- Severe malnutrition
- Febrile condition due to diseases other than malaria, such as measles, acute lower respiratory infection or other known chronic diseases
- Regular medication which might interfere with antimalarial pharmacokinetics
- History of hypersensitivity reactions or contraindications to any medicine being used in the trial.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: Artemether/lumefantrine
In this single-arm study, patients will be treated with Artemether/lumefantrine, and the first, third and fifth doses of the drug will be given under the direct observation of the health workers.
The patients will be followed-up for 42 days, on day 1, 2, 3, 7, 14, 21, 28 and 42 to assess the efficacy of the drug.
|
Blood samples will be collected on blood slides and filter papers for asexual parasites assessment both by microscope and molecular genotyping respectively following treatment with artemether-lumefantrine, to assess its efficacy.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Proportion of patients without parasitaemia on day 42.
Tidsramme: 42 Days
|
Proportion of patients without parasitaemia or with new infection as corrected by molecular genotyping on day 42 will be used to calculate the efficacy of the trial medicine.
|
42 Days
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Plasma lumefantrine concentration
Tidsramme: 7 days and 14 days
|
Mean plasma lumefantrine concentration among patients on day 7 and day 14 following treatment with artemether/lumefantrine as a predictor of cure rate.
|
7 days and 14 days
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Proportional of patients without parasitaemia on day 42
Tidsramme: 42 days
|
Proportion of patients without parasitaemia on day 42 as purely assessed by molecular genotyping of all collected samples on this day, differentiate between recrudescence and new infection and use it to calculate the efficacy of the trial medicine.
|
42 days
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Studieleder: Andreas Martensson, PhD, Karolinska Institutet
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 3.0.2011
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Plasmodium Falciparum Malaria
-
SanofiMedicines for Malaria VentureFullførtPlasmodium Falciparum-infeksjonBenin, Burkina Faso, Gabon, Kenya, Uganda
-
SanofiMedicines for Malaria VentureAvsluttetPlasmodium Falciparum-infeksjonBenin, Burkina Faso, Gabon, Kenya, Mosambik, Uganda, Vietnam
-
Syamsudin Abdillah,Ph.D, Pharm DApt. Dian Yudianto; Dr. dr Erni J. Nelwan, Sp.PD, Ph.D; Apt.Hesty Utami...FullførtUkomplisert Plasmodium FalciparumIndonesia
-
Novartis PharmaceuticalsRekrutteringUkomplisert Plasmodium Falciparum MalariaElfenbenskysten, Kenya, Ghana, Uganda
-
Medicines for Malaria VentureFullførtUkomplisert Plasmodium Falciparum MalariaUganda, Benin, Burkina Faso, Kongo, Den demokratiske republikken, Gabon, Mosambik, Vietnam
-
Karolinska University HospitalMuhimbili University of Health and Allied SciencesFullførtUkomplisert Plasmodium Falciparum MalariaTanzania
-
University of OxfordEuropean CommissionFullførtMalaria | Plasmodium FalciparumStorbritannia
-
University of OxfordRekrutteringMalaria | Plasmodium FalciparumStorbritannia
-
University of OxfordEuropean and Developing Countries Clinical Trials Partnership (EDCTP); Medical...RekrutteringMalaria, Plasmodium FalciparumGambia
-
Centers for Disease Control and PreventionMinistry of Health, LiberiaFullførtMalaria | Plasmodium Falciparum | Ukomplisert malariaLiberia
Kliniske studier på Artemether-lumefantrine
-
University of OxfordMahidol University; Mahidol Oxford Tropical Medicine Research UnitAvsluttetSunn | Farmakokinetisk | MedikamentkombinasjonThailand
-
London School of Hygiene and Tropical MedicineRadboud University Medical Center; Centre national de recherche et de formation...Fullført
-
Novartis PharmaceuticalsMedicines for Malaria VentureFullførtAkutt ukomplisert Falciparum MalariaBurkina Faso, Benin, Kongo, Nigeria, Å gå
-
University of OxfordUniversity of KinshasaFullført
-
University of OxfordMahidol University; Mahidol Oxford Tropical Medicine Research UnitRekrutteringSunn | Farmakokinetisk | MedikamentkombinasjonThailand
-
Dafra PharmaKenya Medical Research InstituteFullført
-
University of LiverpoolInfectious Diseases Institute, Makerere University College of Health... og andre samarbeidspartnereRekrutteringMalaria, FalciparumUganda
-
NovartisFullførtMalaria | FalciparumBenin, Kenya, Mali, Mosambik, Tanzania
-
Centers for Disease Control and PreventionIfakara Health Research and Development CentreFullført